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Introduction
There has been much focus recently on the cardiovascular risk of commonly used nonsteroidal anti-inflammatory drugs (NSAIDs). In 2007, the American Heart Association published a focused update discouraging the use of NSAIDs for patients with established cardiovascular disease.
1 Despite this, many patients with cardiovascular disease receive NSAIDs, albeit for shorter periods. We have previously demonstrated not only that NSAIDs are harmful among patients with myocardial infarction(MI) or heart failure but also that this risk is prevalent even after short treatment periods. 2 Establishing the cardiovascular safety profile of NSAIDs is imperative since patients with established cardiovascular disease and the general population widely use NSAIDs. MI is associated with a high risk of death and recurrent cardiovascular events, especially immediately following MI. The risk of death or recurrent MI after the first MI is elevated in the year after the initial event but approximates baseline levels after 5-10 years.
Because using NSAIDs after the first MI has been demonstrated to increase the risk of death or recurrent MI, understanding the long-term trends in this condition is important: whether using
NSAIDs presents the greatest risk in the first year after the first MI and declines as the years pass or whether using NSAIDs changes the declining incidence of cardiovascular risk in the years after the first MI. If the latter is true, long-term caution with these agents after MI may need to be recommended. This uncertainty prompted us to examine the cardiovascular risk associated with episodes of NSAID use in relation to time elapsed after MI in a nationwide cohort of patients with first-time MI in Denmark.
Methods

Study Design and Data Sources
This study was a nationwide cohort study of patients with first-time MI in Denmark. The study widely use NSAIDs. MI is associated with a high risk of death and recurrent car rd di diov ov vas scu cu cula la lar r r events, especially immediately following MI. The risk of death or recurrent MI after the first MI k s s e ele le leva va vat te ted d d in in in the e e y y yea e r after the initial event but ap ap app pr roximates bas sel el e ine e le le lev v vels after 5-10 years.
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Participants
dispensed from pharmacies in Denmark since 1995. 4 The Registry classifies eac ch h h dr dr rug g g a acc cc ccor or ordi ding g o the international Anatomical Therapeutic Chemical (ATC) system and includes information ab bou ou out t st st stre re eng ng ngth th th, fo fo orm rm rmulation, date of dispensing an an and d quantity dispe e ens n n ed d d. . f
We obt btai ai aine ne ed d in in info fo orm rm mat at atio io ion n ab ab abou ou o t t p p patie en ent ts' v v vit ta al s st sta at atus us s ( (de dea ad has been validated with a specificity exceeding 90%. 5 The first admission for MI implied that the Danish National Patient Registry had not registered any earlier admission for MI in the previous 19 years. This method has been used previously. 2, 6 To avoid selection bias in the exposure allocation caused by the high mortality associated with the MI, the cohort was restricted to individuals still alive 30 days after discharge. We followed the patients until the outcome of interest, emigration or the end of the study period (December 31, 2009), whichever came first.
Drug Use
Denmark's health care system reimburses some medicine expenses, and all pharmacies are thus required to register all dispensed drug prescriptions, which ensures complete registration. During the study period, the only NSAID available in Denmark over the counter without a prescription 
Dose and Duration of Treatment
The Danish Registry of Medicinal Product Statistics does not include information on the prescribed daily dosage of the medication. We therefore estimated the daily dosage when each new prescription was dispensed by calculating the average dosages from up to 7 consecutive prescriptions. This method allowed the dosage to change when a new prescription was dispensed. The method used to determine the dose and treatment duration has been described previously.
8, 9
Comorbidity
We defined comorbidity using diagnoses at discharge from index MI as specified in the Ontario acute MI mortality prediction rules. 10 To further enhance the comorbidity index, we identified discharge diagnoses up to 1 year before the index hospitalization. 11 To define high-risk patients, we used concomitant use of loop diuretics or glucose-lowering drugs as proxies for heart failure or diabetes, respectively.
9
Study Outcome
The study outcomes examined were: 1) all-cause death and 2) the combined endpoint of death caused by coronary artery disease (coronary death, ICD-10 codes I20-I25) or readmission for nonfatal MI (ICD-10 codes I21-I22).
Statistical Analysis
We calculated unadjusted rates of death and of the composite endpoint of coronary death or the incidence of nonfatal recurrent MI per 100 person-years for NSAID treatment in general. We We defined comorbidity using diagnoses at discharge from index MI as specified ed d i in n n th h he e e On On Onta ta tari rio acute MI mortality prediction rules. 10 To further enhance the comorbidity index, we identified di isc sc cha ha har rg rge e di di dia ag gno o ose se ses s up to 1 year before the index ex ex h ho ospitalization n. . 11 To o d de define high-risk patients, w we u used concom om mita an ant t us use e e of of of l l loo o oop p di di d u ur ure e eti ic cs o or r g g gluc c cos se-l lo low we wer ri r n ng ng d d dru u ugs gs a a as pr pro ox oxi ie ies s fo fo for r he he hear art t t f fa fail i i u u ure or r d d dia ia abe be b te tes, s, s, r r res esp pe pec ct tiv ive e ely. y. y.
Terms for all individual NSAIDs were included, with the reference composed of those not taking any NSAIDs at that time. Exposure to NSAIDs was included as a time-dependent covariate in the models, ensuring that patients were only considered at risk when exposed to the respective drug. Each individual could have multiple independent treatment courses with the same drug but also with different drugs. To analyze time variation in risk, we defined 6 exposure periods up to 5 years after discharge from the first MI and included them as time-dependent covariates in the proportional hazard models. All models were adjusted for age, sex, year of index hospitalization, concomitant medication, comorbidity and socioeconomic status. Table 1 lists the variables. We found the assumptions on proportional hazards, the linearity of continuous variables and lack of interaction to be valid unless otherwise indicated.
We performed Cox proportional hazard analysis with time-dependent variables and incidence rates using the Stata statistical package, version 11 (Stata-Corp LP, College Station, TX, USA). We performed all other statistical analysis and data management using the SAS statistical software package, version 9.2 (SAS Institute, Cary, NC, USA).
Results
Patients
From 1997 to 2009, 128,418 patients were admitted with first-time MI; 99,187 (77%) were alive 30 days after discharge and were included in the study. Men comprised 64% of the study cohort, and the mean age was 69 (standard deviation (SD) 13.0) years. Of the 99,187 patients included, 43,608 (44%) filled at least one prescription of NSAIDs nteraction to be valid unless otherwise indicated.
We performed Cox proportional hazard analysis with time-dependent variables and n nci ci ide de den nc nce e ra ra rate te tes us us usi in ing the Stata statistical packag g ge, e, e v v version 11 (Sta a ata t t -C Cor or orp p p LP, College Station, T TX, , US U A). We We p p per r rfo or rm med ed ed a a all ll ll o o oth the e er r st sta a ati is stica a al anal ly ys sis a an nd nd d d da a ata ta m m ma an anag agem em emen en nt t t u us usin ing g g th th the e SA A AS S during follow-up. Us Use e e of of of d dic iclo lo lofe f fena nac c w wa was s s as as sso soci ci iat at a ed ed ed w w wi it ith h th th he e e h hi high gh hes es e t t t r ri isk sk k ( (Fi Fi Figu gu gure re re 3 3 3). )
We c cal al alcu cu ula la ate te ted d th th he in in inci ci cide e enc nc nce e e ra r te te tes s of of of t the he he c c com om mpo p p si si site te te e e end nd ndpo po poin n nt t t o o of f f co co coro ro rona na nary ry ry d d dea ea eath th t s or of the cohort treated with NSAIDs had an unmeasured confounder or a combination of confounders, the confounder would have to elevate the risk by a factor of 4.4-5.4 to explain the increased risk of all-cause mortality observed in our study (Supplemental Figure 4) . Using the Wald test, we examined interactions between the use of NSAID and the available covariates and found no clinically important interactions. Terms for all individual NSAIDs were included, with the reference composed of those not taking any NSAIDs at that time. To determine whether the prevalence of use of the various other medicines affected the estimates, we repeated the models with the reference group only comprising the patients who did not take any NSAID at any time.
The results remained the same (not shown). To analyze the impact of adjusting the Cox models, we calculated the crude hazard ratios for all-cause mortality (Supplemental Table 1a ) and coronary death or nonfatal recurrent MI (Supplemental Table 2a ). Further, we analyzed the effect of age and sex (Supplemental Tables 1b-c Table 3 ).
Discussion
We examined the cardiovascular risk of NSAIDs in relation to the time elapsed after first-time MI in this nationwide study. We demonstrated that the proportional increase in the risk of death and of a composite endpoint of coronary death or nonfatal recurrent MI in post-MI patients receiving NSAIDs was independent of the time elapsed after their first MI. Notably, the risk associated with using NSAIDs remained virtually unchanged throughout all 5 years after discharge from hospital after the first MI.
The risks of cardiovascular mortality and morbidity are well-known complications after MI. The risk is highest soon after the MI but declines as time passes and eventually corresponds we calculated the crude hazard ratios for all-cause mortality (Supplemental Tab ble to the risk of the background population after 5-10 years. 12 However, knowledge about the cardiovascular safety of NSAIDs in the years following MI is limited. Although we also previously reported an increased risk of death and reinfarction associated with using NSAID among such patients, we did not specifically analyze whether the risk associated with NSAIDs depended on the time elapsed after the primary event in that study. 9 We demonstrated doserelated excess mortality associated with the use of NSAIDs, and our results indicated an acute or subacute effect of NSAIDs, since the events were closely tied to the timing of taking the drugs.
To our knowledge, the present study is the first one designed to focus on the risk of death and a composite of coronary death and nonfatal MI associated with NSAIDs in relation to the time elapsed after MI. We found that the use of NSAIDs was associated with a persistently increased cardiovascular risk in the years following MI, thus indicating that the cardiovascular risk of taking NSAIDs during the first year after MI remains similar to that after 5 years. The incidence rates showed persistent increased absolute risks during the 5 years among the patients taking any NSAID, whereas the risk among the patients not taking NSAIDs declines: for example, the risk decreases substantially after the first MI (Figures 2 and 4) . Since these drugs are widely used and concern about their safety is growing, further investigation is needed to clarify whether longterm caution in using these agents after MI should be recommended. It would seem prudent to limit NSAID use among patients with cardiovascular disease and to get the message out to clinicians taking care of these patients that NSAIDs are potentially harmful, even 5 years after MI. Thus, a persistent focus on the risk of NSAIDs is warranted among patients who have experienced MI.
Clinical Implications
Along with other recent reports of the adverse cardiovascular effects of NSAIDs, the current data elapsed after MI. We found that the use of NSAIDs was associated with a persis st te tent nt tly ly y i i inc nc ncre re reas as a e ed cardiovascular risk in the years following MI, thus indicating that the cardiovascular risk of t a aki ki ing ng ng N N NSA SA SAID ID IDs du du duri ring the first year after MI rem m mai ain ns similar to t tha ha h t af af fte te ter r r 5 years. The incidence a ate e es s showed p per er rsi ist ten en nt in in incr cr crea ea eas se sed d ab ab abso so olu u ute r ri isk k ks d du ur r ring g g t t the he 5 y yea ea ars s a amo mo on ng g t the he he p pat at tie ie i n nt nts s ta taki ki king ng g a a any NS NS SAI AI AID, D, D, w whe he here reas as s t the he h r r ris sk k k am am mon on o g g g th th the e e pa pa ati ti ien en ent ts ts n n not ot o t t tak ak kin n ng g g NS NS NSAI AI IDs Ds Ds d d dec ec ecli lin ne nes: s: f f for or o e e exa xa amp m mple e e, t th the e r r ris sk sk decreases su ubs bs sta ta ant nt tia ia iall l y y y af a a te e er r r th th t e e e fi fi firs rs st t t MI MI MI ( ( (Fi Fi Figu gu worrying that the use of NSAIDs remains high 24 even though the risk of these drugs is well established in the literature, and particularly worrying that some NSAIDs remain available over the counter. 9, 25 Among the conventional nonselective NSAIDs, the cardiovascular risk of naproxen has been much debated, but it is widely accepted that naproxen is probably the NSAID with the safest cardiovascular risk profile, and some reports have even suggested that naproxen protects against cardiovascular risk. 22, 26, 27 In accordance with other studies, we found that naproxen was the NSAID with the lowest relative cardiovascular risk, and the results might indicate that naproxen should be preferred if NSAID treatment cannot be avoided. Nevertheless, naproxen was associated with a higher risk of gastrointestinal bleeding than rofecoxib, and gastrointestinal bleeding among patients with MI is associated with poor prognosis. 28 Indeed, the adverse prognostic effects of gastrointestinal bleeding further support a very conservative approach to using NSAIDs among patients with MI. The absence of large-scale comparative trials of long-term safety and efficacy hampers determining the appropriate pain relief for patients with established cardiovascular disease. Thus, large systematic reviews of the risks and benefits of a broad range of various analgesic agents are warranted. 29, 30 Epidemiological studies such as ours cannot establish causality, but in a field of research with no randomized controlled trials, we find it particularly important to report associations between drugs and adverse events naproxen has been much debated, but it is widely accepted that naproxen is proba ba abl bl ly y th th the e e NS NS NSA A AID y with the safest cardiovascular risk profile, and some reports have even suggested that naproxen pr rot ot tec ec ects ts ts a aga ga gain in inst c c ca ar ardi d ovascular risk. 22, 26, 27 In ac c cco co c r rd dance with ot the he h r st stud ud udie i s, we found that n napr prox o en was s t the he h N N NSA SA SAID ID D w wit it ith h h th the e e lo lo l w we wes st re e ela a ative e e c c card d dio io ova vasc sc cul ula a ar r r ris isk, k k an n nd d th th the e e re resu su sult lt lts s mi mi m gh gh ght t t n ndi di dica ca ate te t t tha ha at t t na nap pr pro ox oxen en n s sho ho h ul uld d d be be be p p pre re refe ferr rr r ed ed ed i i if f f NS NS NSA A AID D D t tr trea ea atm tm tmen en nt t t c c cann nn nnot ot be e e av av voi oi oide de d d d. d. N N Nev v ver r rth the el eles es ss, s naproxen was as s a a ass ss s oc oc ocia ia i te te t d d d wi wi with th th a a a h h hig ig i he he h r r ri ri r sk sk sk o o of f f g g gas as str tr roi oi oint ntes es esti ti ina na nal bl bl blee e e f f f di di ding ng ng t t tha ha han n n ro ro ofe fe feco co coxi xi xib, b and that can affect patient prognosis.
Strengths and Limitations
The strength of this study lies in its completeness of data from a whole country. Confounding by indication may have contributed to the results, and we acknowledge that lack of information about the indications for NSAID treatment is a limitation of the study.
However, such confounding probably cannot fully explain our results. To test for these biases, we performed sensitivity analysis that supported our results. Rheumatic diseases are common reasons for NSAID use, and previous studies have reported an increased risk of coronary artery ablets. Such NSAID use having major effects in this study is therefore unlikely. . To To To con on o fi fi firm rm rm o our esults, we performed sensitivity analysis with the study period ending on November 1, 2001.
Th he e e re re es su sult lt lts s s re re ema a ain in ined ed unchanged (not shown). Th Th he e m m main limitatio on n n is i inh nh nhe e erent in the disease among patients with rheumatoid arthritis. [31] [32] [33] We therefore performed the analysis excluding patients with rheumatoid arthritis, which did not change the results (not shown). The risk differed between the individual NSAIDs, which are used for similar indications, and the degree of COX-2 inhibition (as reported in the literature) was clearly correlated with the risk, which also indicates the predominant importance of the drugs (rather than the drug indications)
for the results. Moreover, we have previously reported a clear dose-dependent increase in risk associated with NSAIDs. 9 Further, given the evidence from randomized controlled trials and other observational studies of adverse cardiovascular effects of selective COX-2 inhibitors and nonselective NSAIDs, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] we do not believe that confounding by indication alone could have driven the results. This is further supported by the fact that an unmeasured confounder had to elevate the risk more than 4-fold to explain the risk increase by NSAIDs we demonstrated. We found a stronger relation to all cause mortality ratherr than cause specific mortality, which may be due to an underestimation of the cardiovascular component in death registration of these patients. We were studying a group of patients with a major coronary event and we therefore find it likely that most deaths in this population are influenced by the coronary component. Thus when these patients die from pulmonary disease, infection etc -then death was influenced by their heart disease.
Aspirin is available over the counter, which explains why the fraction of patients who fill prescriptions for aspirin is relatively low. Another consequence of this is that we do not have information on whether using NSAIDs may lead to prematurely discontinuing aspirin. We assume that most patients who did not fill a prescription for aspirin were treated with over-thecounter aspirin, since medication adherence has been documented to be high among patients in Denmark after MI. 27, 34 Our use of prescription data without knowing whether patients adhere to driven the results. This is further supported by the fact that an unmeasured conf fou ou und nd der r r h h had ad ad t t to o o elevate the risk more than 4-fold to explain the risk increase by NSAIDs we demonstrated. We fo oun un und d d a a a st st stro ro rong nger r r r re el elat a ion to all cause mortality r rat at athe err than cause sp s s ec cif if ific ic ic mortality, which may b be e d d due u to an u und nd der er res sti ti tima ma ati ti tion on on o o of f th th he e ca card rdi iova a asc c cula a ar c com m mp po pon n nen nt nt i in n n d de deat ath h h r re egi gi is st str ra rati tion on on o o of f f th th t e es ese e pa pati ti tien en nts ts t . . We We We w wer er re st stud ud dyi yi ing ng a a a g gro ro roup up up o of f f pa pa ati ti tien en ents ts s w wi i ith h h a ma ma ajo jo jor r co co coro ro ona na ary ry ry e e eve ve ent nt a a and nd nd w w we e e th the e ere ef efor ore e e f fi find n treatment is another possible bias. Patients may not take their prescribed medication, and unfortunately, there is no way around this problem in observational studies. Nevertheless, nonadherence would tend to dilute the observed association between the exposure and outcome.
Information bias is another limitation, as patients do not necessarily take their medicines as prescribed and in temporal sequence.
Conclusion
In conclusion, our study demonstrated that NSAID use among patients with first-time MI was associated with persistently increased risk of all-cause mortality and of a composite of coronary death or nonfatal recurrent MI, respectively, for at least 5 years thereafter. These results support previous findings that NSAIDs have no apparent safe treatment window among patients with MI.
Further studies are warranted to evaluate the cardiovascular safety of NSAIDs, but at this point the overall evidence suggests advising caution in using NSAIDs at all times after MI. Funding Sour ur rce ce c s: s: s: An An Anne ne n -M M Mar ar arie e e S S Sch ch hje j j rn rn rnin in ng g g Ol Ol Olse se s n n n ha ha has s re re ece ce ceiv iv ived ed ed a a an n n un un unre re rest st stri ri rict ct cted ed d g g gra ra rant nt n f f fro r m the 
